ArticleRadiology2023
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.
Abstract read
In one paragraph
Article in Radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial.La Radiologia medica · 2026Trial
- PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.European urology open science · 2026Review
- Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.European radiology · 2026Article
- Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026Article
- [BJUI compass · 2026Article
- PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [European journal of nuclear medicine and molecular imaging · 2026Article
- Imaging of Small Lung Nodules on Modern SAFOV and LAFOV PET in Combination With Data-driven Motion Correction: Implications for Current Practice.Clinical nuclear medicine · 2026Article
- Prognostic Value of the SUVmax-IPI Composite Score on Overall Survival in Metastatic Prostate Cancer.Journal of clinical medicine · 2026Article
- M2 macrophage related genes predict prognosis and drug response in prostate cancer.Discover oncology · 2026Article
- Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.European journal of nuclear medicine and molecular imaging · 2026Article
- MRI-based risk stratification for predicting overall survival in pancreatic ductal adenocarcinoma.Insights into imaging · 2025Article
- A fully automated AI-based method for tumour detection and quantification on [EJNMMI physics · 2025Article
- How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.European urology open science · 2025Article
- Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.European journal of nuclear medicine and molecular imaging · 2025Article
- Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [Physical and engineering sciences in medicine · 2025Article
- Review
- Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Molecular tumor volume on PSMA PET/CT is an independent imaging biomarker associated with progression-free survival in patients with oligorecurrent prostate cancer.American journal of nuclear medicine and molecular imaging · 2025Article
- Impact of Surgical Margin Status and Tumor Volume on Mortality After Robotic Radical Prostatectomy.European urology open science · 2025Article
- Correlation of [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Robert SeifertFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0001-5985-7701
Sazan RasulFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0003-2898-3232
Konstantin E SeifertFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-9109-9004
Maria EveslageFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-8802-1134
Laya Rahbar NikoukarFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0003-3213-8568
Katharina KesselFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
Michael SchäfersFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-4008-2755
Josef YuFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0003-1426-1538
Alexander R HaugFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-8308-6174
Marcus HackerFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-4222-4083
Martin BögemannFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-2569-4446
Lisa BodeiFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
Michael J MorrisFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
Michael S HofmanFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0001-8622-159X
Kambiz RahbarFrom the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).ORCID 0000-0002-4591-4055
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Background Prostate-specific membrane antigen (PSMA) PET has high specificity in localizing primary tumors and metastases in patients with prostate cancer, but the individual overall survival probability is still difficult to estimate. Purpose To develop a prognostic risk score using PSMA PET-derived organ-specific total tumor volumes for predicting overall survival in patients with prostate cancer. Materials and Methods Men with prostate cancer who underwent PSMA PET/CT from January 2014 to December 2018 were evaluated retrospectively. All patients from center A were split into training (80%) and internal validation (20%) cohorts. Randomly selected patients from center B were used for external validation. Organ-specific tumor volumes were automatically quantified from PSMA PET scans by a neural network. A prognostic score was selected using multivariable Cox regression guided by the Akaike information criterion (AIC). The final prognostic risk score fitted on the training set was applied to both validation cohorts. Results A total of 1348 men (mean age, 70 years ± 8 [SD]) were included, with 918 patients in the training cohort, 230 in the internal validation cohort, and 200 in the external validation cohort. The median follow-up time was 55.7 months (IQR, 46.7-65.1 months; >4 years; 429 deaths occurred). A body weight-adjusted prognostic risk score integrating total, bone, and visceral tumor volumes obtained high C index values in the internal (0.82) and external (0.74) validation cohorts, as well as in patients with castration-resistant (0.75) and hormone-sensitive (0.68) disease. The fit of the statistical model for the prognostic score was improved compared with a model containing total tumor volume only (AIC, 3324 vs 3351; likelihood ratio test,
Indexed as
Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedGallium RadioisotopesHumansMalePrognosisRetrospective StudiesRisk FactorsTumor BurdenGallium Radioisotopes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.